inclusion criteria: * patients 18 to 80 years old with sars-cov-2 infection (positive crp \<10 days from the onset of symptoms) treated in primary health care. * persistent respiratory symptoms (more than 1 and \<12 months of evolution) * mild-moderate dyspnea: score at the beginning of the study according to the modified medical research council (mmrc) scale from 0 to 3 * the patient must be competent to complement the follow-up evaluations. * the patient agrees to participate in the study and take assigned medication during the 4 weeks. * sign the informed consent

inclusion criteria: * patients 18 to 80 years old with sars-cov-2 infection (positive crp \<10 days from the onset of symptoms) treated in primary health care. * persistent respiratory symptoms (more than 1 and \<12 months of evolution) * mild-moderate dyspnea: score at the beginning of the study according to the modified medical research council (mmrc) scale from 0 to 3 * the patient must be competent to complement the follow-up evaluations. * the patient agrees to participate in the study and take assigned medication during the 4 weeks. * sign the informed consent

inclusion criteria: patients 18 to 80 years old with sars-cov-2 infection (positive crp <10 days from the onset of symptoms) treated in primary health care. persistent respiratory symptoms (more than 1 and <12 months of evolution) mild-moderate dyspnea: score at the beginning of the study according to the modified medical research council (mmrc) scale from 0 to 3 the patient must be competent to complement the follow-up evaluations. the patient agrees to participate in the study and take assigned medication during the 4 weeks. sign the informed consent

inclusion criteria: patients 18 to 80 years old with sars-cov-2 infection (positive crp <10 days from the onset of symptoms) treated in primary health care. persistent respiratory symptoms (more than 1 and <12 months of evolution) mild-moderate dyspnea: score at the beginning of the study according to the modified medical research council (mmrc) scale from 0 to 3 the patient must be competent to complement the follow-up evaluations. the patient agrees to participate in the study and take assigned medication during the 4 weeks. sign the informed consent

inclusion criteria: - patients 18 to 80 years old with sars-cov-2 infection (positive crp <10 days from the onset of symptoms) treated in primary health care. - persistent respiratory symptoms (more than 1 and <3 months of evolution) - mild-moderate dyspnea: score at the beginning of the study according to the modified medical research council (mmrc) scale from 0 to 3 - the patient must be competent to complement the follow-up evaluations. - the patient agrees to participate in the study and take assigned medication during the 4 weeks. - sign the informed consent

inclusion criteria: - patients 18 to 80 years old with sars-cov-2 infection (positive crp <10 days from the onset of symptoms) treated in primary health care. - persistent respiratory symptoms (more than 1 and <3 months of evolution) - mild-moderate dyspnea: score at the beginning of the study according to the modified medical research council (mmrc) scale from 0 to 3 - the patient must be competent to complement the follow-up evaluations. - the patient agrees to participate in the study and take assigned medication during the 4 weeks. - sign the informed consent